secwatch.observer — SEC 8-K summary
======================================

Issuer:     ELITE PHARMACEUTICALS INC /NV/ (ELTP)
CIK:        0001053369
Form:       8-K
Filed at:   2023-12-26T23:59:59+00:00
Accession:  0001493152-23-046142
Event type: regulatory
Sentiment:  neutral
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Elite Pharmaceuticals files ANDA for generic CNS stimulant; market $5.1B
------------------------------------------------------------------------

- ANDA accepted for review by FDA on Dec 21, 2023 for undisclosed generic CNS stimulant.
- IQVIA reports annual brand and generic market sales of $5.1B for this product (12 months to June 2023).
- Elite operates a cGMP and DEA-registered facility in Northvale, NJ for R&D and manufacturing.
- No launch timeline or revenue guidance provided; approval and commercialization still pending.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223046142/0001493152-23-046142-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1053369/000149315223046142/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-046142

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer